tiprankstipranks
Trending News
More News >
NEUSOFT XIKANG HOLDINGS INC. (HK:9686)
:9686
Hong Kong Market
Advertisement

NEUSOFT XIKANG HOLDINGS INC. (9686) AI Stock Analysis

Compare
0 Followers

Top Page

HK:9686

NEUSOFT XIKANG HOLDINGS INC.

(9686)

Rating:44Neutral
Price Target:
HK$1.00
▲(5.26%Upside)
The overall score reflects significant financial challenges due to declining revenue and ongoing losses, despite some cash flow improvements. Technical analysis shows mixed signals with short-term upward trends but potential bearish momentum. Valuation remains weak due to negative earnings and lack of dividends.

NEUSOFT XIKANG HOLDINGS INC. (9686) vs. iShares MSCI Hong Kong ETF (EWH)

NEUSOFT XIKANG HOLDINGS INC. Business Overview & Revenue Model

Company DescriptionNeusoft Xikang Holdings Inc. (9686) is a leading company in the healthcare technology sector, focusing on the development and provision of innovative digital health solutions. The company offers a wide range of products and services designed to enhance healthcare delivery and patient outcomes, including cloud-based healthcare platforms, medical devices, and health management services. Neusoft Xikang leverages cutting-edge technology to drive efficiency and effectiveness in healthcare systems.
How the Company Makes MoneyNeusoft Xikang Holdings Inc. generates revenue through a diversified business model centered around its digital health solutions. The company earns money from the sale and licensing of its proprietary healthcare platforms and software solutions to hospitals, clinics, and other healthcare providers. Additionally, revenue is generated from the sale of medical devices and equipment. Neusoft Xikang also offers health management and consulting services, which provide recurring income streams. The company has established strategic partnerships with healthcare institutions and technology firms, further enhancing its market reach and revenue potential. Key factors contributing to its earnings include its ability to innovate in digital health and its strong presence in the rapidly growing healthcare technology market.

NEUSOFT XIKANG HOLDINGS INC. Financial Statement Overview

Summary
The company faces significant profitability and revenue challenges, impacting the income statement negatively. However, the balance sheet shows signs of stabilization with improving equity, and cash flows are turning positive, suggesting potential recovery if trends continue.
Income Statement
45
Neutral
The company demonstrates a consistent decline in revenue from 2022 to 2024, with a significant decrease in net income, resulting in negative net profit margins. Both EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges and profitability issues.
Balance Sheet
55
Neutral
The balance sheet shows improvement with a positive stockholders' equity in 2023 and 2024, although the company still has a high debt-to-equity ratio due to substantial liabilities. The equity ratio remains low, indicating a potential risk in financial stability despite improved equity.
Cash Flow
60
Neutral
Cash flow improved in 2024 with positive operating and free cash flows, reversing previous negative trends. The operating cash flow to net income ratio reflects a better alignment between cash flow generation and accounting income, yet the free cash flow growth is volatile.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue501.50M537.72M687.41M614.30M503.01M
Gross Profit147.50M164.61M168.45M170.23M134.11M
EBITDA-52.06M-75.65M-161.41M-214.71M-101.65M
Net Income-83.05M-154.65M-241.97M-296.54M-196.43M
Balance Sheet
Total Assets1.26B1.40B934.45M946.85M954.64M
Cash, Cash Equivalents and Short-Term Investments797.70M856.13M351.76M364.91M419.87M
Total Debt574.47M603.44M573.44M456.28M446.23M
Total Liabilities892.31M964.28M1.38B1.21B1.09B
Stockholders Equity363.31M428.14M-451.98M-274.55M-132.99M
Cash Flow
Free Cash Flow21.56M-24.42M-81.17M-101.77M-124.13M
Operating Cash Flow21.56M-20.16M-73.83M-83.38M-17.30M
Investing Cash Flow110.45M-146.60M-8.45M-5.47M-195.16M
Financing Cash Flow-56.56M504.77M64.62M64.90M216.29M

NEUSOFT XIKANG HOLDINGS INC. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.95
Price Trends
50DMA
0.94
Positive
100DMA
0.87
Positive
200DMA
0.83
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
55.93
Neutral
STOCH
55.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9686, the sentiment is Positive. The current price of 0.95 is above the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.94, and above the 200-day MA of 0.83, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.93 is Neutral, neither overbought nor oversold. The STOCH value of 55.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9686.

NEUSOFT XIKANG HOLDINGS INC. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
HK$20.97B39.2328.81%0.71%14.99%31.70%
61
Neutral
HK$17.74B5.78-7.44%3.51%11.55%-28.15%
53
Neutral
HK$1.45B-18.19%-24.50%-93.44%
53
Neutral
HK$790.49M-18.64%41.62%-22.27%
50
Neutral
HK$3.26B-2.19%5.32%89.43%
45
Neutral
HK$5.95B-2.97%11.00%56.87%
44
Neutral
HK$799.78M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.95
0.15
18.75%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
43.85
32.28
279.00%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
13.14
0.18
1.39%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.95
1.24
72.51%
HK:2158
Yidu Tech, Inc.
6.58
3.00
83.80%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.47
0.73
98.65%

NEUSOFT XIKANG HOLDINGS INC. Corporate Events

Xikang Cloud Hospital Grants Share Options to Boost Stakeholder Alignment
Jul 21, 2025

Xikang Cloud Hospital Holdings Inc. announced the grant of 28,990,000 share options to 236 eligible participants under its Post-IPO Share Option Scheme. The options, which have an exercise price of HK$0.904 per share, are subject to a vesting schedule over three years and performance targets based on financial and business-related indicators. The scheme includes a clawback mechanism for violations of laws or company rules, ensuring alignment with company goals and stakeholder interests.

Xikang Cloud Hospital Holdings to Optimize Fund Usage with Cash Management Strategy
Jun 13, 2025

Xikang Cloud Hospital Holdings Inc. announced its decision to use idle proceeds from its global offering for cash management by investing in high-security, liquid wealth management products. This strategic move, involving up to US$40 million, is intended to enhance fund usage efficiency and protect shareholder interests without affecting the company’s normal operations or the intended use of proceeds.

Xikang Cloud Hospital Holdings Inc. Successfully Passes All AGM Resolutions
May 22, 2025

Xikang Cloud Hospital Holdings Inc. held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed. These included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting mandates for share issuance and repurchase. The adoption of the ninth amended Memorandum and Articles of Association was also approved, indicating strategic governance updates.

Xikang Cloud Hospital Announces Equity Disposal and Capital Increase
May 20, 2025

Xikang Cloud Hospital Holdings Inc. announced a connected transaction involving the disposal of equity interests in a target company and a capital increase arrangement. Xikang Healthcare Technology, a subsidiary of Xikang Cloud Hospital, agreed to transfer its equity interest in the target company to Neutech, while Neutech will also participate in a capital increase for the target company. This transaction will result in a dilution of Xikang Cloud Hospital’s shareholding in the target company, and it complies with the reporting requirements under the Listing Rules, though it is exempt from independent shareholders’ approval.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 29, 2025